EFG Asset Management North America Corp. Raises Stock Holdings in Insulet Co. (NASDAQ:PODD)

EFG Asset Management North America Corp. boosted its holdings in Insulet Co. (NASDAQ:PODD) by 32.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,266 shares of the medical instruments supplier’s stock after purchasing an additional 2,296 shares during the period. EFG Asset Management North America Corp.’s holdings in Insulet were worth $2,420,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in Insulet in the fourth quarter worth about $69,433,000. Alecta Tjanstepension Omsesidigt bought a new position in shares of Insulet during the 4th quarter valued at approximately $53,184,000. Proficio Capital Partners LLC purchased a new stake in shares of Insulet during the 4th quarter worth approximately $28,422,000. Baillie Gifford & Co. raised its holdings in shares of Insulet by 3.5% in the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock worth $614,998,000 after purchasing an additional 79,982 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new position in Insulet in the third quarter valued at approximately $16,342,000.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Raymond James reissued an “outperform” rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Wells Fargo & Company lifted their price objective on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Stifel Nicolaus upped their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a report on Friday, February 21st. Canaccord Genuity Group increased their target price on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Finally, Citigroup boosted their price target on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insider Transactions at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.47% of the stock is owned by insiders.

Insulet Stock Down 0.5 %

PODD opened at $272.71 on Wednesday. The firm has a market capitalization of $19.15 billion, a P/E ratio of 47.10, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The company has a fifty day moving average price of $272.27 and a 200-day moving average price of $258.19. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Equities research analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.